NATCO Pharma LimitedNSE: NATCOPHARM

Press Release May 03 2021

· Issued by NATCO Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

The approval was granted by the Central Drugs Standard Control Organization in India for multiple strengths of the medication. NATCO plans to request a Compulsory License due to the public health emergency and aims to launch the product imminently.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

NATCO Pharma Limited on 6ix

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases